Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: Involvement of regulatory T cells

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Hegde, V. L.
  • Hegde, S.
  • Cravatt, Benjamin
  • Hofseth, L. J.
  • Nagarkatti, M.
  • Nagarkatti, P. S.

publication date

  • July 2008

journal

  • Molecular Pharmacology  Journal

abstract

  • Immune-mediated liver diseases including autoimmune and viral hepatitis are a major health problem worldwide. Natural cannabinoids such as Delta(9)-tetrahydrocannabinol (THC) effectively modulate immune cell function, and they have shown therapeutic potential in treating inflammatory diseases. We investigated the effects of THC in a murine model of concanavalin A (ConA)-induced hepatitis. Intraperitoneal administration of THC after ConA challenge inhibited hepatitis as shown by significant decrease in liver enzymes and reduced liver tissue injury. Furthermore, THC treatment resulted in significant suppression of crucial inflammatory cytokines in ConA-induced hepatitis. It is noteworthy that THC treatment in ConA-injected mice led to significant increase in absolute number of Forkhead helix transcription factor p3+ T regulatory cells in liver. We were surprised to find that select cannabinoid receptor (CB1 or CB2) agonists were not able to block hepatitis either independently or in combination. However, CB1/CB2 mixed agonists were able to efficiently attenuate hepatitis similar to THC. The modulatory effect of THC in ConA-induced hepatitis was reversed by both CB1 and CB2 antagonists. We also observed that endogenous cannabinoid anandamide was able to reduce hepatitis by suppressing cytokine levels. In addition, deficiency or inhibition of endocannabinoid hydrolyzing enzyme fatty acid amide hydrolase (FAAH), which leads to increased levels of endogenous cannabinoids, resulted in decreased liver injury upon ConA challenge. Our data demonstrate that targeting cannabinoid receptors using exogenous or endogenous cannabinoids and use of FAAH inhibitors may constitute novel therapeutic modalities to treat immune-mediated liver inflammation.

subject areas

  • Alanine Transaminase
  • Animals
  • Apoptosis
  • Arachidonic Acids
  • Aspartate Aminotransferases
  • Cannabinoid Receptor Modulators
  • Cells, Cultured
  • Chemokines
  • Concanavalin A
  • Cytokines
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Dronabinol
  • Endocannabinoids
  • Female
  • Hepatitis, Autoimmune
  • Hepatocytes
  • In Situ Nick-End Labeling
  • Leukocytes
  • Liver
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Polyunsaturated Alkamides
  • Receptors, Cannabinoid
  • T-Lymphocytes, Regulatory
  • Time Factors
  • Treatment Outcome
scroll to property group menus

Identity

PubMed Central ID

  • PMC2828293

International Standard Serial Number (ISSN)

  • 0026-895X

Digital Object Identifier (DOI)

  • 10.1124/mol.108.047035

PubMed ID

  • 18388242
scroll to property group menus

Additional Document Info

start page

  • 20

end page

  • 33

volume

  • 74

issue

  • 1

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support